Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Next Previous
X
Search
Trial Profile

Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary) ; Antineoplastics
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AZURE

    • Most Recent Events

    • 25 May 2021 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 Results assessing MAF biomarker for response prediction by using data from two studies including this study presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 07 Feb 2018 Results of a study assessing predictive role of serum bone biomarkers in identifying patients with a high risk of developing bone metastasis published in the Journal of the National Cancer Institute

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top